Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
Michael A Singer,1 Steven R Cohen,2 Sylvia L Groth,3 Salman Porbandarwalla2
1Medical Center Ophthalmology Associates (MCOA), San Antonio, Texas, USA; 2Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA; 3University of Minnesota Medical School, Minneapolis, Minnesota, USA
Purpose: To examine short-term effects of ranibizumab versus bevacizumab on reduction of optical coherence tomography (OCT) central macular thickness (CMT) in patients with macular edema secondary to retinal vein occlusions (RVOs).
Methods: This is a retrospective analysis in which patients with RVOs were injected with either bevacizumab or ranibizumab. At 2 weeks, all patients were injected with a dexamethasone intravitreal implant (Ozurdex®). CMT on OCT and best-corrected visual acuity were obtained at baseline, at 2 weeks (just prior to the dexamethasone intravitreal implant), and 6 weeks.
Results: Sixty-four patients received injections (32 bevacizumab; 32 ranibizumab). At 2 weeks, bevacizumab group had a mean (±standard error of mean [SEM]) CMT reduction of 26.2% ± 3.4% versus 47% ± 3.5% reduction with ranibizumab (P < 0.0001). At 6 weeks, there was a 31.6% ± 3.2% CMT reduction with bevacizumab versus 52% ± 3.2% with ranibizumab (P < 0.0001). At 2 weeks, 15 (9%) of bevacizumab patients versus 25 (78.1%) ranibizumab patients achieved OCT CMT < 300 µm (P = 0.0192). At 6 weeks, 18 (56.3%) of bevacizumab compared to 30 (93.8%) of ranibizumab patients achieved CMT < 300 µm (P = 0.0010). Visual acuity was not significantly different at each time interval between the groups.
Conclusion: Ranibizumab appears to have a greater effect in the short-term of decreasing macular edema on OCT when compared to bevacizumab in patients with RVOs.
Keywords: anti-VEGF, central macular thickness, dexamethasone, intravitreal implant, macular edema, retinal vein occlusion
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]